Findings on Prostate Cancer Described by Researchers at Oulu University Hospital (External beam radiation for the treatment of castration-resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome ...)
By a News Reporter-Staff News Editor at Drug Week Investigators publish new report on Oncology - Prostate Cancer. According to news originating from Oulu, Finland, by NewsRx correspondents, research stated, "Patients who undergo early androgen-deprivation therapy for prostate cancer may eventually develop castration-resistant prostate cancer. However, no optimal treatment for non-metastasized castration-resistant prostate cancer has yet been established."
Our news journalists obtained a quote from the research from Oulu University Hospital, "In the present retrospective, single-institutional study, the radiotherapy (RT) outcomes were evaluated in patients who underwent androgen-deprivation therapy for non-metastatic prostate cancer and subsequently developed castration-resistant disease. Following a thorough chart review, the data of 21 patients with castration-resistant prostate cancer who were treated between 2000 and 2010 with external beam radiation therapy (EBRT) at a prostate radiation dose of >45 Gy were evaluated. Of the 21 patients, 16 (76%) developed biochemical recurrence after RT, with a mean time to biochemical recurrence of 17 months. A total of 18 patients succumbed to the disease during follow-up, with a mean survival of 3 years after RT. A radiation dose of >66 Gy was associated with a longer time to biochemical recurrence after RT (p=0.011) and a longer survival, compared with a dose of less than or equal to66 Gy (p=0.028). The mean overall survival time after RT was 42 months and did not depend on the primary hormonal treatment. Prostate-specific survival time was negatively associated with the Gleason score at diagnosis. The prostate-specific antigen (PSA) concentration prior to RT was a prognostic factor for biochemical recurrence of prostate cancer after RT, as well as for prostate cancer-specific survival. Finally, the multivariate analysis revealed that age, PSA concentration prior to RT and a high Gleason score were independent prognostic factors for prostate cancer-specific survival. Overall, our study findings demonstrated that disease progression was common after EBRT for castration-resistant prostate cancer and that survival was limited."
According to the news editors, the research concluded: "However, young patients and those with low-risk disease at the time of diagnosis may benefit from RT."
For more information on this research see: External beam radiation for the treatment of castration-resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome of 21 patients. Molecular and Clinical Oncology, 2017;6(3):428-432 (see also Oncology - Prostate Cancer).
The news correspondents report that additional information may be obtained from T. Kuusk, Division of Operative Care and Medical Research Center Oulu, Oulu University Hospital, 90220 Oulu, Finland. Additional authors for this research include K. Pulliainen and M.H Vaarala.
Keywords for this news article include: Oulu, Europe, Finland, Oncology, Androgens, Biochemicals, Biochemistry, Prostate Cancer, Drugs and Therapies, Prostatic Neoplasms.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC